BridgeBio Oncology Therapeutics (BBOT) risk factors, FY2024 10-K

BridgeBio Oncology Therapeutics's FY2024 10-K, filed Mar 11, 2025, lists 65 risk factors in 5 groups. There is no earlier 10-K to compare against, so the most company-specific risks are listed below.

Risk factors listed
655 groups
Section length
30k wordsItem 1A

BridgeBio Oncology Therapeutics's biggest risks in the FY2024 10-K

  • This company is a special purpose acquisition company (SPAC) formed to complete an initial business combination, specifically the BBOT Business Combination.
  • Risks are dominated by shareholder redemption mechanics, trust account protections, and potential target qualification issues.
  • Operations and investments depend entirely on successfully acquiring a target business within the allotted completion window.

The risks most specific to BridgeBio Oncology Therapeutics

  • Risks Relating to our Search for, and Consummation of or Inability to Consummate, a business combination

    Your only opportunity to effect your investment decision regarding a potential business combination may be limited to the exercise of your right to redeem your shares from us for cash

    Your only opportunity to influence your investment may be limited to redeeming shares for cash, as you cannot evaluate the BBOT Business Combination in advance and directors may complete it without shareholder approval.

  • Risks Relating to our Search for, and Consummation of or Inability to Consummate, a business combination

    As of December 31, 2024, our initial shareholders owned 4,600,000 founder shares, which represented 20% of our issued and outstanding ordinary shares

    Initial shareholders own 4,600,000 founder shares representing 20% of outstanding ordinary shares, giving them substantial influence over shareholder votes.

  • Risks Relating to our Search for, and Consummation of or Inability to Consummate, a business combination

    The ability of our public shareholders to redeem their shares for cash may make our financial condition unattractive to potential business combination targets, which may make it difficult for us to enter into a business combination with a target

    Minimum cash requirements in the BBOT Business Combination Agreement or target agreements may make our financial condition unattractive to potential targets.

  • Risks Relating to our Search for, and Consummation of or Inability to Consummate, a business combination

    We may not be able to complete our initial business combination within the completion window, in which case we would redeem our Public Shares

    We may fail to find a suitable target and complete the BBOT Business Combination within the completion window, forcing us to redeem Public Shares.

  • Risks Relating to our Search for, and Consummation of or Inability to Consummate, a business combination

    If third parties bring claims against us, the proceeds held in the Trust Account could be reduced and the per-share redemption amount received by shareholders may be less than $10.00 per share

    Third-party claims could reduce the Trust Account proceeds below $10.00 per share, lowering the per-share redemption amount.

  • Risks Relating to our Search for, and Consummation of or Inability to Consummate, a business combination

    Changes in laws or regulations, or a failure to comply with any laws and regulations, may adversely affect our business, including our ability to negotiate and complete our initial business combination, and results of operations, including the BBOT Business Combination

    Compliance with evolving regulations by governing bodies like the SEC could hinder our ability to negotiate and complete the BBOT Business Combination.

  • Risks Relating to our Search for, and Consummation of or Inability to Consummate, a business combination

    We may seek business combination opportunities in industries or sectors that may be outside of our management’s areas of expertise

    If the BBOT Business Combination fails, we may pursue candidates outside our management's areas of expertise.

  • Risks Relating to our Search for, and Consummation of or Inability to Consummate, a business combination

    We do not have a specified maximum redemption threshold. The absence of such a redemption threshold may make it possible for us to complete our initial business combination with which a substantial majority of our shareholders do not agree

    The absence of a maximum redemption threshold allows us to complete the BBOT Business Combination even if a substantial majority of shareholders disagree.

  • Risks Relating to the Post-Business Combination Company

    We may reincorporate in or transfer by way of continuation to another jurisdiction in connection with our initial business combination, and the laws of such jurisdiction may govern some or all of our future material agreements and we may not be able to enforce our legal rights

    We may reincorporate outside the Cayman Islands for the BBOT Business Combination, subjecting material agreements to foreign laws that may complicate legal enforcement.

All 65 risk factors

Headings as the filing states them, in filing order.

Risks Relating to our Search for, and Consummation of or Inability to Consummate, a business combination

  1. 01Your only opportunity to effect your investment decision regarding a potential business combination may be limited to the exercise of your right to redeem your shares from us for cash
  2. 02As of December 31, 2024, our initial shareholders owned 4,600,000 founder shares, which represented 20% of our issued and outstanding ordinary shares
  3. 03The ability of our public shareholders to redeem their shares for cash may make our financial condition unattractive to potential business combination targets, which may make it difficult for us to enter into a business combination with a target
  4. 04The ability of our public shareholders to exercise redemption rights with respect to a large number of our shares could increase the probability that our initial business combination would be unsuccessful and that you would have to wait for liquidation in order to redeem your shares
  5. 05We may not be able to complete our initial business combination within the completion window, in which case we would redeem our Public Shares
  6. 06We may decide not to extend the term we have to consummate our initial business combination, in which case we would redeem our Public Shares
  7. 07If a shareholder fails to receive notice of our offer to redeem our Public Shares in connection with our initial business combination, or fails to comply with the procedures for submitting or tendering its shares, such shares may not be redeemed
  8. 08You will not be entitled to protections normally afforded to investors of other blank check companies subject to Rule 419 of the Securities Act
  9. 09If third parties bring claims against us, the proceeds held in the Trust Account could be reduced and the per-share redemption amount received by shareholders may be less than $10.00 per share
  10. 10Our directors may decide not to enforce the indemnification obligations of our Sponsor, resulting in a reduction in the amount of funds in the Trust Account available for distribution to our public shareholders
  11. 11We may not have sufficient funds to satisfy indemnification claims of our Sponsor, Cormorant, directors and officers
  12. 12Changes in laws or regulations, or a failure to comply with any laws and regulations, may adversely affect our business, including our ability to negotiate and complete our initial business combination, and results of operations, including the BBOT Business Combination
  13. 13If we are unable to consummate our initial business combination within the completion window, our public shareholders may be forced to wait beyond the end of the completion window before redemption from our Trust Account
  14. 14Our shareholders may be held liable for claims by third parties against us to the extent of distributions received by them upon redemption of their shares
  15. 15We may not hold an annual general meeting until after the consummation of our initial business combination, which could delay the opportunity for our shareholders to appoint directors
  16. 16Because we are neither limited to evaluating a target business in a particular industry sector nor have we selected any target businesses with which to pursue our initial business combination, you will be unable to ascertain the merits or risks of any particular target business’s operations
  17. 17We may seek business combination opportunities in industries or sectors that may be outside of our management’s areas of expertise
  18. 18Unlike some other similarly structured special purpose acquisition companies, our initial shareholders will receive additional Class A ordinary shares if we issue certain shares to consummate an initial business combination
  19. 19We may issue our shares to investors in connection with our initial business combination at a price which is less than the prevailing market price of our shares at that time
  20. 20We may engage in a business combination with one or more target businesses that have relationships with entities that may be affiliated with our Sponsor, officers, directors or existing holders which may raise potential conflicts of interest
  21. 21We may issue notes or other debt securities, or otherwise incur substantial debt, to complete a business combination, which may adversely affect our leverage and financial condition and thus negatively impact the value of our shareholders’ investment in us
  22. 22We may attempt to simultaneously complete business combinations with multiple prospective targets, which may hinder our ability to complete our initial business combination and give rise to increased costs and risks that could negatively impact our operations and profitability
  23. 23We may attempt to complete our initial business combination with a private company about which little information is available, which may result in a business combination with a company that is not as profitable as we suspected, if at all
  24. 24We do not have a specified maximum redemption threshold. The absence of such a redemption threshold may make it possible for us to complete our initial business combination with which a substantial majority of our shareholders do not agree
  25. 25We may be unable to obtain additional financing to complete our initial business combination or to fund the operations and growth of a target business, which could compel us to restructure or abandon a particular business combination
  26. 26Our initial shareholders control a substantial interest in us and thus may exert a substantial influence on actions requiring a shareholder vote, potentially in a manner that you do not support
  27. 27Because we must furnish our shareholders with target business financial statements, we may lose the ability to complete an otherwise advantageous initial business combination with some prospective target businesses
  28. 28Compliance obligations under the Sarbanes-Oxley Act may make it more difficult for us to effectuate our initial business combination, require substantial financial and management resources, and increase the time and costs of completing an initial business combination

Risks Relating to the Post-Business Combination Company

  1. 29Our management may not be able to maintain control of a target business after our initial business combination. We cannot provide assurance that, upon loss of control of a target business, new management will possess the skills, qualifications or abilities necessary to profitably operate such business
  2. 30We may reincorporate in or transfer by way of continuation to another jurisdiction in connection with our initial business combination, and the laws of such jurisdiction may govern some or all of our future material agreements and we may not be able to enforce our legal rights
  3. 31We may reincorporate in another jurisdiction, which may result in taxes imposed on our shareholders
  4. 32The officers and directors of an acquisition candidate may resign upon completion of our initial business combination. The loss of a business combination target’s key personnel could negatively impact the operations and profitability of our post-combination business
  5. 33We may seek business combination opportunities with a high degree of complexity that require significant operational improvements, which could delay or prevent us from achieving our desired results
  6. 34If our management following our initial business combination is unfamiliar with U.S. securities laws, they may have to expend time and resources becoming familiar with such laws, which could lead to various regulatory issues

Risks Relating to Acquiring and Operating a Business in Foreign Countries

  1. 35If we effect our initial business combination with a company located outside of the United States, we would be subject to a variety of additional risks that may adversely affect us
  2. 36Exchange rate fluctuations and currency policies may cause a target business’ ability to succeed in the international markets to be diminished
  3. 37If we acquire a non-U.S. target, our results of operations may be negatively impacted because of the costs and difficulties inherent in managing cross-border business operations
  4. 38If social unrest, acts of terrorism, regime changes, changes in laws and regulations, political upheaval or policy changes or enactments occur in a country in which we may operate after we effect our initial business combination, it may result in a negative impact on our business
  5. 39Many countries have difficult and unpredictable legal systems and underdeveloped laws and regulations that are unclear and subject to corruption and inexperience, which may adversely impact our results of operations and financial condition
  6. 40Because foreign law could govern almost all of our material agreements, we may not be able to enforce our rights within such jurisdiction or elsewhere, which could result in a significant loss of business, business opportunities or capital

Risks Relating to Our Sponsor and Management Team

  1. 41We are dependent upon our officers and directors and their loss, or a reduction in the amount of time they can dedicate to our initial business combination, could adversely affect our ability to operate
  2. 42Our officers and directors will allocate their time to other businesses thereby causing conflicts of interest in their determination as to how much time to devote to our affairs. This conflict of interest could have a negative impact on our ability to complete our initial business combination
  3. 43Our officers, directors, security holders and their respective affiliates may have competitive pecuniary interests that conflict with our interests
  4. 44Members of our management team and affiliated companies may have been, and may in the future be, involved in civil disputes or governmental investigations unrelated to our business
  5. 45Our Letter Agreement with our Sponsor, officers, directors and advisors may be amended without shareholder approval

Risks Relating to our Securities

  1. 46You will not have any rights or interests in funds from the Trust Account, except under certain limited circumstances. Therefore, to liquidate your investment, you may be forced to sell your Public Shares, potentially at a loss
  2. 47If we are unable to consummate our initial business combination within the completion window, our public shareholders may be forced to wait beyond such completion window before redemption from our Trust Account
  3. 48Nasdaq may delist our Class A ordinary shares from trading on its exchange, which could limit investors’ ability to make transactions in our securities and subject us to additional trading restrictions
  4. 49The grant of registration rights to our initial shareholders and holders of our Private Placement Shares may make it more difficult to complete our initial business combination, and the future exercise of such rights may adversely affect the market price of our Class A ordinary shares
  5. 50Our initial shareholders have paid an aggregate of $25,000, or approximately $0.009 per founder share and, accordingly, you will experience immediate and substantial dilution from the purchase of our Class A ordinary shares
  6. 51Implied value per share upon consummation of initial business combination(2) $ 7.58
  7. 52(2) All founder shares would automatically convert into Class A ordinary shares upon completion of our initial business combination or earlier at the option of the holder
  8. 53We are a blank check company with no operating history and no revenues, and you have no basis on which to evaluate our ability to achieve our business objective
  9. 54Past performance by our management team, our advisors and their respective affiliates, including investments and transactions in which they have participated and businesses with which they have been associated, may not be indicative of future performance of an investment in the Company
  10. 55The 1% U.S. federal excise tax on stock buybacks could be imposed on redemptions of our stock if we were to become a “covered corporation” in the future
  11. 56An investment in our securities may result in uncertain U.S. federal income tax consequences
  12. 57After our initial business combination, it is possible that a majority of our directors and officers will live outside the United States and all of our assets will be located outside the United States; therefore, investors may not be able to enforce federal securities laws or their other legal rights
  13. 58Because we are incorporated under the laws of the Cayman Islands, you may face difficulties in protecting your interests, and your ability to protect your rights through the U.S. Federal courts may be limited
  14. 59Provisions in our Articles may inhibit a takeover of us, which could limit the price investors might be willing to pay in the future for our Class A ordinary shares and could entrench management
  15. 60Cyber incidents or attacks directed at us could result in information theft, data corruption, operational disruption and/or financial loss
  16. 61Our Articles provide that the courts of the Cayman Islands will be the exclusive forums for certain disputes between us and our shareholders, which could limit our shareholders’ ability to obtain a favorable judicial forum for complaints against us or our directors, officers or employees
  17. 62Changes in the market for directors and officers liability insurance could make it more difficult and more expensive for us to negotiate and complete an initial business combination
  18. 63Recent increases in inflation in the United States and elsewhere could make it more difficult for us to complete our initial business combination
  19. 64We are subject to changing law and regulations regarding regulatory matters, corporate governance and public disclosure that have increased both our costs and the risk of non-compliance
  20. 65We employ a mail forwarding service, which may delay or disrupt our ability to receive mail in a timely manner

Other BridgeBio Oncology Therapeutics 10-Ks

  • FY2025 10-K risk factors
    90 risks90 new65 dropped

    BridgeBio Oncology Therapeutics transitioned from a SPAC shell company to an operating biopharmaceutical firm following its business combination in May 2024.

    Filed Mar 05, 2026

About this page

The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.